ATHE

Business Context and Reporting Period

Company: Prana Biotechnology Limited (Note: Request metadata listed "Alterity Therapeutics," but the filing text identifies the registrant as Prana Biotechnology Limited).

Reporting Period: Fiscal year ended June 30, 2014.

Business Overview: Prana is an Australian biotechnology company in the development stage, focused on creating therapeutic drugs for neurodegenerative diseases, specifically Alzheimer's, Huntington's, and Parkinson's disease. The company's lead product candidate, PBT2, is in Phase II clinical trials for Alzheimer's and Huntington's disease. A second candidate, PBT434, is in pre-clinical development for Parkinson's disease and movement disorders. The company has no commercial product revenue and relies on equity financing, grants, and tax incentives to fund operations.

Key Financial Metrics (Year Ended June 30, 2014)

Note: All figures are in Australian Dollars (A$). The company reported no debt as of June 30, 2014, having repaid a convertible promissory note to the Alzheimer's Drug Discovery Foundation (ADDF) during the year.

Material Changes vs. Prior Period

• Increased R&D Spend: Research and development expenses increased by 81.7% (A$6.7 million) to A$14.9 million. This was driven by the completion of the "Reach2HD" Huntington's disease trial, the "IMAGINE" Alzheimer's disease trial, and the initiation of new API manufacturing campaigns.
• Higher Tax Incentive Income: Other income increased by 74.8% to A$7.8 million, primarily due to the Australian Government's 45% refundable R&D tax offset on eligible activities.
• Significant Cash Inflow: Cash and cash equivalents more than doubled to A$34.2 million. This was fueled by A$32.4 million raised through the At-The-Market (ATM) facility and A$4.95 million from option exercises.
• Foreign Exchange Loss: The company recorded a foreign exchange loss of A$746,593, compared to a gain of A$140,761 in the prior year, due to the appreciation of the Australian dollar against the U.S. dollar.
• Increased Operating Costs: Auditor and accounting expenses doubled (106% increase) due to SOX 404 compliance costs. Travel and public relations expenses also saw significant increases (219% and 163% respectively) due to expanded clinical trial oversight and investor communications.

Guidance, Outlook, and Risks

Outlook and Guidance: The company does not provide specific financial guidance. Management expects to continue incurring operating losses as it advances clinical trials for PBT2 and PBT434. The company plans to seek additional funding through public/private financings, licensing, or strategic alliances to meet long-term objectives. Management believes current cash reserves, combined with potential future capital raises and R&D tax refunds, are sufficient to fund operations for at least 12 months.

Key Risks and Contingencies:

• Development Risk: Success is uncertain; clinical trials may fail to demonstrate safety or efficacy. Positive results in early trials (e.g., PBT2) do not guarantee success in later stages.
• Liquidity Risk: The company has no commercial revenue and relies on capital markets. Failure to raise additional funds could force a curtailment of operations.
• Manufacturing Dependence: The company relies on a sole manufacturer (Dr. Reddy's) for PBT2 API and a sole encapsulator (Patheon). Disruption could cause significant delays.
• Regulatory Risk: Approval by the FDA, TGA, and EMA is required for commercialization. Delays or rejections would materially harm the business.
• PFIC Status: The company believes it qualifies as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which may subject U.S. investors to adverse tax consequences.

Important Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the A$34.2 million cash balance against the projected burn rate for ongoing Phase II trials and future Phase III preparations.
• Clinical Trial Results: Review the detailed results of the "Reach2HD" (Huntington's) and "IMAGINE" (Alzheimer's) trials. While safety was confirmed, the IMAGINE trial did not show significant changes in the primary endpoint (amyloid burden), though there were trends in preserving brain volume.
• Orphan Drug Designation: Confirm the impact of the FDA Orphan Drug designation granted to PBT2 for Huntington's disease (announced September 2014, post-period end) on regulatory strategy and potential market exclusivity.
• R&D Tax Incentive Reliance: Assess the sustainability of the business model given the heavy reliance on the Australian R&D tax offset (A$7.8 million in 2014) to offset operating losses.
• Capital Structure: Monitor the dilution impact of the At-The-Market (ATM) facility and outstanding options (16.4 million options outstanding as of June 30, 2014).